News and Announcements
Prescient Therapeutics Secures $7.0M Capital Raising
- Published May 18, 2016 4:26PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th May 2016, ASX Announcement
- $7.0 M institutional placement
- Rights issue on same terms to raise up to a further $3.4 M
Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to advise the successful completion of of an institutional placement to raise $7.0 million.
The placement, largely to life-science focused Australian institutional investors, has been undertaken which will involve the issue of approximately 77.7 million shares at 9.0 cents per share with 1 attaching option for every 2 shares subscribed (exercisable at 18 cents; expiring 30 June 2018). The placement will be undertaken in two tranches. The first tranche of approximately 19.4 million shares will be unconditional, with shareholders to approve the second tranche (of approximately 58.3 million) and all attaching options.
To view the full announcement, please click on the button below.